# Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

> **NCT06796803** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 398 (estimated)

## Conditions studied

- Potentially Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** camrelizumab combined with rivoceranib and HAIC
- **DRUG:** camerlizumab + rivoceranib

## Key facts

- **NCT ID:** NCT06796803
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2028-02-20
- **Final completion:** 2030-02-28
- **Target enrollment:** 398 (ESTIMATED)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796803, "Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06796803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*